Pyxis Oncology (PYXS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

PYXS Stock Forecast

Pyxis Oncology stock forecast is as follows: an average price target of $9.00 (represents a 328.57% upside from PYXS’s last price of $2.10) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

PYXS Price Target

The average price target for Pyxis Oncology (PYXS) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $7.00. This represents a potential 328.57% upside from PYXS's last price of $2.10.

PYXS Analyst Ratings

Buy

According to 3 Wall Street analysts, Pyxis Oncology's rating consensus is 'Buy'. The analyst rating breakdown for PYXS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pyxis Oncology Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 16, 2024	Swayampakula Ramakanth	H.C. Wainwright	-	-	98.86%	233.33%
Aug 07, 2024	Bradley Canino	Stifel Nicolaus	-	-	219.49%	376.19%
May 07, 2024	Farzin Haque	Jefferies	-	-	132.02%	376.19%

Row per page

Go to

The latest Pyxis Oncology stock forecast, released on Aug 16, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $7.00, which represents a 98.86% increase from the stock price at the time of the forecast ($3.52), and a 233.33% increase from PYXS last price ($2.10).

Pyxis Oncology Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$9.00
Last Closing Price	$2.10	$2.10	$2.10
Upside/Downside	-100.00%	-100.00%	328.57%

In the current month, the average price target of Pyxis Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pyxis Oncology's last price of $2.10. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 05, 2023	RBC Capital		Outperform	Initialise
Apr 25, 2022	Zacks Investment Research		Hold	Upgrade

Row per page

Go to

Pyxis Oncology's last stock rating was published by H.C. Wainwright on Aug 16, 2024. The company gave PYXS a "Buy" rating, the same as its previous rate.

Pyxis Oncology Financial Forecast

Pyxis Oncology Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$9.33M	$2.83M	-	-	-	-	-	-	$125.00K	$125.00K	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$4.13M	$200.00K	$833.00K	$625.00K
High Forecast	$9.33M	$2.83M	-	-	-	-	-	-	$125.00K	$125.00K	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$4.13M	$200.00K	$833.00K	$625.00K
Low Forecast	$9.33M	$2.83M	-	-	-	-	-	-	$125.00K	$125.00K	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$4.13M	$200.00K	$833.00K	$625.00K
# Analysts	1	1	-	-	-	-	-	-	1	1	1	1	1	1	3	1	3	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Pyxis Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYXS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Pyxis Oncology EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
# Analysts	1	1	-	-	-	-	-	-	1	1	1	1	1	1	3	1	3	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-17.77M	$-25.35M	$-18.12M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict PYXS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pyxis Oncology's previous annual EBITDA (undefined) of $NaN.

Pyxis Oncology Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
# Analysts	1	1	-	-	-	-	-	-	1	1	1	1	1	1	3	1	3	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-15.60M	$-23.05M	$-15.90M
Avg Forecast	$-18.94M	$-20.36M	$-20.00M	$-20.14M	$-19.82M	$-19.96M	$-20.10M	$-20.24M	$-18.67M	$-19.13M	$-18.82M	$-19.73M	$-18.90M	$-19.33M	$-20.54M	$-14.49M	$-28.83M	$-30.78M	$-39.27M
High Forecast	$-18.94M	$-20.36M	$-20.00M	$-20.14M	$-19.82M	$-19.96M	$-20.10M	$-20.24M	$-18.67M	$-19.13M	$-18.82M	$-17.34M	$-16.54M	$-19.33M	$-20.54M	$-14.49M	$-20.59M	$-30.78M	$-39.27M
Low Forecast	$-18.94M	$-20.36M	$-20.00M	$-20.14M	$-19.82M	$-19.96M	$-20.10M	$-20.24M	$-18.67M	$-19.13M	$-18.82M	$-22.72M	$-22.44M	$-19.33M	$-20.54M	$-14.49M	$-33.54M	$-30.78M	$-39.27M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.54%	0.75%	0.40%

Pyxis Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYXS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Pyxis Oncology SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
# Analysts	1	1	-	-	-	-	-	-	1	1	1	1	1	1	3	1	3	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.16M	$10.67M	$6.73M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Pyxis Oncology's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PYXS last annual SG&A of $6.16M (Dec 23).

Pyxis Oncology EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
# Analysts	1	1	-	-	-	-	-	-	1	1	1	1	1	1	3	1	3	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.27	$-0.00	$-0.41
Avg Forecast	$-0.31	$-0.34	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.31	$-0.32	$-0.31	$-0.33	$-0.31	$-0.32	$-0.34	$-0.24	$-0.47	$-0.51	$-0.65
High Forecast	$-0.31	$-0.34	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.31	$-0.32	$-0.31	$-0.29	$-0.27	$-0.32	$-0.34	$-0.24	$-0.34	$-0.51	$-0.65
Low Forecast	$-0.31	$-0.34	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.33	$-0.31	$-0.32	$-0.31	$-0.37	$-0.37	$-0.32	$-0.34	$-0.24	$-0.55	$-0.51	$-0.65
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.57%	0.00%	0.63%

According to undefined Wall Street analysts, Pyxis Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYXS previous annual EPS of $NaN (undefined).

Pyxis Oncology Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	-	-	1375.41%	Buy
XFOR	X4 Pharmaceuticals	-	-	891.89%	Buy
INZY	Inozyme Pharma	-	-	445.35%	Buy
PYXS	Pyxis Oncology	-	-	328.57%	Buy
PDSB	PDS Bio	-	-	309.09%	Buy
ZURA	Zura Bio	-	-	241.30%	Buy
TERN	Terns Pharmaceuticals	-	-	149.56%	Buy
MREO	Mereo BioPharma Group	-	-	83.42%	Buy
HOOK	HOOKIPA Pharma	-	-	30.43%	Buy
CRVS	Corvus Pharmaceuticals	-	-	19.35%	Buy
EFTR	eFFECTOR Therapeutics	-	-	-	Buy

PYXS Forecast FAQ

Is Pyxis Oncology a good buy?

Yes, according to 3 Wall Street analysts, Pyxis Oncology (PYXS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PYXS's total ratings.

What is PYXS's price target?

Pyxis Oncology (PYXS) average price target is $9 with a range of $7 to $10, implying a 328.57% from its last price of $2.1. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pyxis Oncology stock go up soon?

According to Wall Street analysts' prediction for PYXS stock, the company can go up by 328.57% (from the last price of $2.1 to the average price target of $9), up by 376.19% based on the highest stock price target, and up by 233.33% based on the lowest stock price target.

Can Pyxis Oncology stock reach $3?

PYXS's average twelve months analyst stock price target of $9 supports the claim that Pyxis Oncology can reach $3 in the near future.

What are Pyxis Oncology's analysts' financial forecasts?

Pyxis Oncology's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-80.113M (high $-80.113M, low $-80.113M), average SG&A $0 (high $0, low $0), and average EPS is $-1.319 (high $-1.319, low $-1.319). PYXS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $12.16M (high $12.16M, low $12.16M), average EBITDA is $0 (high $0, low $0), average net income is $-79.433M (high $-79.433M, low $-79.433M), average SG&A $0 (high $0, low $0), and average EPS is $-1.308 (high $-1.308, low $-1.308).